Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV

Helen Ayles, Albertus Schaap, Amos Nota, Charalambos Sismanidis, Ruth Tembwe, Petra De Haas, Monde Muyoyeta, Nulda Beyers, Peter Godfrey-Faussett for the ZAMSTAR Study Team, Helen Ayles, Albertus Schaap, Amos Nota, Charalambos Sismanidis, Ruth Tembwe, Petra De Haas, Monde Muyoyeta, Nulda Beyers, Peter Godfrey-Faussett for the ZAMSTAR Study Team

Abstract

Background: The Stop TB Partnership target for tuberculosis is to have reduced the prevalence of tuberculosis by 50% comparing 2015 to 1990. This target is challenging as few prevalence surveys have been conducted, especially in high burden tuberculosis and HIV countries. Current tuberculosis control strategies in high HIV prevalent settings are therefore based on limited epidemiological evidence and more evidence is needed from community-based surveys to inform improved policy formulation.

Methods and findings: 8044 adults were sampled from 2 sub-districts (wards) in Lusaka province, Zambia. Questionnaires were used to screen for symptoms, respiratory samples were obtained for culture and oral secretions collected for HIV testing. 79 individuals were found to have Mycobacterium tuberculosis in their sputum, giving an adjusted overall prevalence of tuberculosis of 870/100,000 (95% CI 570-1160/100,000). The adjusted overall prevalence of HIV was 28.61% (95% CI 26.04-31.19). HIV- infection was significantly associated with prevalent tuberculosis (Adj OR 2.3, 95% CI 1.42-3.74) and the population attributable fraction of HIV for prevalent tuberculosis was 36%. Symptoms such as prolonged cough (adj OR 12.72, 95% CI 7.05-22.94) and fever (Adj OR 2.04, 95%CI 1.23-3.39), were associated with prevalent tuberculosis, but 8 (10%) individuals with prevalent tuberculosis denied having any symptoms at all and only 34 (43%) would have been classified as a TB suspect by current guidelines.

Conclusions: Undiagnosed tuberculosis is a challenge for tuberculosis control and new approaches are needed if we are to reach international targets. Epidemiological studies can inform screening algorithms for both detection and prevention of active tuberculosis.

Figures

Figure 1. Algorithm for Decision on Clinical…
Figure 1. Algorithm for Decision on Clinical TB.
Figure 2. Flowchart of Individuals within the…
Figure 2. Flowchart of Individuals within the Study.

References

    1. Corbett E, Watt CJ, Walker N, Maher D, Lazzari S, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch InternMed. 2003;163:1009–1021.
    1. United Nations. Millennium Development Goals. 2000 (Last accessed 15/02/07)
    1. Stop TB Partnership and World Health Organisation. The Global Plan to Stop TB. Geneva: WHO/HTM/STB/2006.35 2006
    1. World Health Organisation. Interim Policy on Collaborative TB/HIV Activities. Geneva 2004
    1. WHO. Epidemiological Country Profile on HIV and AIDS, Zambia. 2008 (Last accessed 24th March 2009)
    1. World Health Organization. Global Tuberculosis Control. Surveillance, Planning, Financing. Geneva: WHO. WHO/HTM/TB/2008.393 2008
    1. Dye C, Bassili A, Bierrenbach AL, Broekmans JF, Chada VK, et al. Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infectious Diseases published online January 16 2008 2008
    1. Aluoch JA, Karuga WK, Nsanzumuhire H, Edwards EA, Stott H, et al. A second study of the use of community leaders in case-finding for pulmonary tuberculosis in Kenya. Tubercle. 1978;59:233–243.
    1. Aluoch JA, Edwards EA, Stott H, Fox W, Sutherland I. A fourth study of case-finding methods for pulmonary tuberculosis in Kenya. Trans R Soc Trop Med Hyg. 1982;76:679–691.
    1. Aluoch JA, Stott H. Case-finding studies in pulmonary tuberculosis in Kenya. East Afr Med J. 1983;60:542–545.
    1. Aluoch JA. A survey to assess passive case-finding in pulmonary tuberculosis in Kenya. East Afr Med J. 1983;60:360–366.
    1. Aluoch JA, Swai OB, Edwards EA, Stott H, Darbyshire JH, et al. Study of case-finding for pulmonary tuberculosis in outpatients complaining of a chronic cough at a district hospital in Kenya. Am Rev Respir Dis. 1984;129:915–920.
    1. Aluoch JA, Swai OB, Edwards EA, Stott H, Darbyshire JH, et al. Studies of case-finding for pulmonary tuberculosis in outpatients at 4 district hospitals in Kenya. Tubercle. 1985;66:237–249.
    1. Corbett EL, Charalambous S, Moloi VM, Fielding K, Grant AD, et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med. 2004;170:673–679.
    1. Corbett EL, Bandason T, Cheung YB, Munyati S, Godfrey-Faussett P, et al. Epidemiology of Tuberculosis in a High HIV Prevalence population provided with Enhanced Diagnosis of Symptomatic Disease. PLoS Medicine. 2007;4:0164–0172.
    1. Elliott AM, Hayes RJ, Halwiindi B, Luo N, Tembo G, et al. The impact of HIV on infectiousness of pulmonary tuberculosis: a community study in Zambia. AIDS. 1993;7:981–987.
    1. Klausner JD, Ryder RW, Baende E, Lelo U, Williame JC, et al. Mycobacterium tuberculosis in household contacts of human immunodeficiency virus type 1-seropositive patients with active pulmonary tuberculosis in Kinshasa, Zaire [published erratum appears in J Infect Dis 1993 Sep;168(3):802]. J-Infect-Dis. 1993;168:106–111.
    1. Tanzania Tuberculin Survey Collaboration. Tuberculosis control in the era of the HIV epidemic: risk of tuberculosis infection in Tanzania, 1983–1998. Int J Tuberc Lung Dis. 2001;5:103–112.
    1. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, et al. HIV and pulmonary tuberculosis: the impact goes beyond those infected with HIV. AIDS. 2004;18:657–662.
    1. den Boon S, van Lill SW, Borgdorff MW, Enarson DA, Verver S, et al. High prevalence of tuberculosis in previously treated patients, Cape Town, South Africa. Emerg Infect Dis. 2007;13:1189–1194.
    1. Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med. 2007;175:87–93.
    1. Mtei L, Matee M, Herfort O, Bakari M, Horsburgh CR, et al. High Rates of Clinical and Subclinical Tuberculosis among HIV-Infected Ambulatory Subjects in Tanzania. Clin Infect Dis. 2005;40:1500–1507.
    1. World Health Organization. Global Tuberculosis Control. Surveillance, Planning, Financing. Geneva: WHO. WHO/HTM/TB/2006.362 2006
    1. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Micro. 1997;35:907–914.
    1. Van Soolingen D, de Haas PEW, Kremer K. Restriction fragment length polymorphism typing of mycobacteria. In: Parisch T, Stoker NG, editors. Mycobacterium tuberculosis protocols. Totowa, N.J.: Humana Press; 2001. pp. 165–203.
    1. World Health Organization. Assessing tuberculosis prevalence through population-based surveys. Geneva 2007
    1. Godfrey-Faussett P, Ayles H. Can we control tuberculosis in high HIV prevalence settings? Tuberculosis (Edinb) 2003;83:68–76.
    1. WHO. TB/HIV Fact sheet. 2008 (Accessed 24th March 2009)
    1. Granich R, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57.
    1. Currie C, Floyd K, Williams BG, Dye C. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health. 2005;5:130.
    1. Ayles H, Muyoyeta M. Isoniazid to prevent first and recurrent episodes of TB. Trop Doct. 2006;36:83–86.
    1. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS. 1999;13:501–507.
    1. Hernandez-Garduno E, Cook V, Kunimoto D, Elwood RK, Black WA, et al. Transmission of tuberculosis from smear negative patients: a molecular epidemiology study. Thorax. 2004;59:286–290.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere